Answers are grounded in this paper and cite their sources.
Demonstrates reduced Mycobacterium tuberculosis in mice using SQ641-NE, indicating potential therapeutic benefit.
A phospholipid-based nanoemulsion formulation of SQ641 (SQ641-NE) was active against intracellular Mycobacterium tuberculosis in J774A.1 mouse macrophages, although SQ641 by itself was not. Intravenous (i.v.) SQ641-NE was cleared from circulation and reached peak concentrations in lung and spleen in 1 h. In a murine tuberculosis (TB) model, 8 i.v. doses of SQ641-NE at 100 mg/kg of body weight over 4 weeks caused a 1.73 log10 CFU reduction of M. tuberculosis in spleen and were generally bacteriostatic in lungs.
No takes yet. Share an insight, caveat, or question.
Nikonenko et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: